Evozyne designs novel therapeutic proteins using generative AI to address challenges in immune-mediated diseases. Their AI-native platform, EvoGen, creates new protein mechanisms optimized for potency, stability, and specificity, which are then built and tested in their EvoLab facility. Evozyne translates these engineered proteins into their pipeline for immune therapies, serving patients with high unmet needs where current treatments fail.